---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-158409"
form_type: "8-K"
ticker: "WAT"
cik: "0001000697"
company_name: "WATERS CORP /DE/"
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:35:44.541430+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal

## Summary
- Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.
- Pro forma 2025 revenue ~$6.5B, adjusted EBITDA ~$2.0B; expected accretive to adj EPS in Y1.
- Targets mid-to-high single-digit revenue growth and mid-teens adj EPS growth annually 2025-2030.
- Anticipates ~$345M annualized EBITDA synergies by 2030: $200M cost by Y3, $290M revenue by Y5.
- Closing expected around end of Q1 2026, subject to regulatory approvals and Waters shareholder vote.

## SEC filing metadata
- accession: 0001193125-25-158409
- form_type: 8-K
- ticker: WAT
- cik: 0001000697
- company_name: WATERS CORP /DE/
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000697/000119312525158409/0001193125-25-158409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000697/000119312525158409/d935060d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-158409
- JSON: https://secwatch.observer/filing/0001193125-25-158409.json
- Plain text: https://secwatch.observer/filing/0001193125-25-158409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.